How One China State-Owned Group Became A Behemoth, Powered By COVID-19
But Will Size, Speed, Policy Support Matter More Than Innovation?
Already producing a broader range of biologics than any biotech firm in the world, from antibodies via plasma products to testing assays to vaccines, the state-owned China National Biotec Group is becoming even bigger with policy support and one surprising helper: the coronavirus pandemic. But might it face challenges from innovators and foreign firms in a changing environment?
